Saturday 17 October 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
17.56
0.78
−4.25%
Follow DNLI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(44.44%) | (45.69%) | (49.59%) | (54.93%) | |
| (39.75%) | (40.69%) | (40.04%) | (44.01%) | ||
ROIC |
(409.82%) | (229.23%) | 0.00% | (260.54%) | |
Return on Tangible Assets |
(58.94%) | (59.97%) | (52.68%) | (71.65%) | |
Average Days of Receivables |
— | — | — | 4.79 | |
Free Cash Flow per Share |
(2.38) | (2.44) | (2.25) | (2.34) | |
Free Cash Flow |
(410.85) | (422.10) | (419.23) | (437.46) | |
Capital Expenditures |
(13.07) | (9.50) | (6.89) | (3.42) | |
| Other line items | |||||
Cash ROIC |
(23.08%) | (22.37%) | (21.84%) | (28.20%) | |
Accounts Receivable Turnover |
— | — | — | 152.28 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.13 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 335.71 | |
Days of Inventory on Hand |
— | — | — | 117.69 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 134.02% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 48.41% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 31.80% | |
Operating CF/Net income |
0.80 | 0.81 | 0.81 | 0.85 | |
Depreciation/Fixed assets |
(0.09) | 0.02 | 0.08 | 0.12 | |
Capex/Depreciation |
2.84 | (10.22) | (1.69) | (0.58) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 1.60 | |
Operating CF per Share |
(2.31) | (2.39) | (2.21) | (2.32) | |
Capex per Share |
(0.08) | (0.05) | (0.04) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 |
Columns are period end dates